GlassScriptPhysician profile
Samantha Mudd
NPI 1043997661
$2,826.76
in general payments reported to CMS, 2019-2025
20 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $412 · 2024: $1,052 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.53 |
| Education | $124.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $720.88 | 2023-2025 | Xifaxan |
| Abbvie INC. | $677.67 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.37 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $262.02 | 2025 | Tremfya |
| Lilly USA, LLC | $167.86 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $138.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $117.27 | 2024 | Stelara, Tremfya |
| Genzyme Corporation | $102.69 | 2023-2025 | |
| Novo Nordisk INC | $55.21 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $51.07 | 2024-2025 | |
| Pfizer INC. | $37.34 | 2024-2025 | |
| Braintree Laboratories, INC. | $33.69 | 2024-2025 | Sutab, Suflave |
| Gilead Sciences, INC. | $29.58 | 2024 | |
| Phathom Pharmaceuticals, INC. | $29.29 | 2025 | Voquezna |
| Aimmune Therapeutics, INC. | $29.18 | 2024-2025 | Zenpep |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $23.29 | 2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $21.70 | 2025 | Dupixent |
| Ardelyx, INC. | $20.69 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $17.09 | 2024 | Iqirvo |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.